drugset
drugset / Trial / NCT02404675

High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation

NCT02404675 ↗

Phase 4 Unknown 240 enrolled Betta Pharmaceuticals Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

This randomized, open-label study is aimed to evaluate the efficacy of high-dose icotinib in treating advanced non-small cell lung cancer patients with positive EGFR 21 exon mutation.

Timeline

Start
2015-04
Primary completion
2017-12
Completion
2018-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Icotinib Small molecule 125 mg —
Subject Icotinib Small molecule 250 mg —

Indications

non-small cell lung carcinoma